Sort   by:  
 Page size 
UnknownPost-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial.
Not available
S-EPMC11381616 | biostudies-literature
UnknownSafety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Not available
S-EPMC10150320 | biostudies-literature
UnknownPitavastatin to Prevent Cardiovascular Disease in HIV Infection.
Not available
S-EPMC10564556 | biostudies-literature
UnknownProtease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.
Not available
S-EPMC4765553 | biostudies-literature
UnknownLong-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
Not available
S-EPMC10867418 | biostudies-literature
UnknownGenome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.
Not available
S-EPMC6465407 | biostudies-literature
UnknownCopy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.
Not available
S-EPMC9537519 | biostudies-literature
UnknownThe predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Not available
S-EPMC8460445 | biostudies-literature
UnknownA case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
Not available
S-EPMC7890067 | biostudies-literature
UnknownIdentification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.
Not available
S-EPMC4962376 | biostudies-literature
Sort   by:  
 Page size